Rationale for the Clinical Application of Flow Cytometry in Patients with Myelodysplastic Syndromes | Aplastic Anemia and MDS International Foundation

Rationale for the Clinical Application of Flow Cytometry in Patients with Myelodysplastic Syndromes

Journal Title: 
Leuk Lymphoma
Author(s): 
van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E
Primary Author: 
van de Loosdrecht AA
Original Publication Date: 
Thursday, August 23, 2012

An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.

Bone Marrow Diseases: